Sunny describes retatrutide as targeting GIP, GLP-1 and glucagon receptors in one weekly shot, calls its phase 3 data strong and asks when FDA approval might come.
Recap by typeshit. Video by Sunny | CAA on TikTok.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
The Facebook post says the triple-agonist shot slows stomach emptying, which can be risky under anesthesia. It also notes the drug has no FDA approval yet.
An indirect comparison of trial results presented at EASD found tirzepatide at 10 mg and 15 mg ahead of higher-dose semaglutide on weight loss.
Loading…